Send to

Choose Destination
JAMA. 2014 May 14;311(18):1870-82. doi: 10.1001/jama.2014.4030.

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Collaborators (191)

Hamilton A, Lehman R, Proietto J, Simons L, Bous JP, Cornelli K, De Munck L, Vantroyen, Vermeersch L, Vileyn G, Akhras R, Cha J, Chehayeb R, Chilvers M, Collette R, Dowell A, Dzongowski P, Gupta A, Halperin F, Hart R, Heaton K, Henein S, Kanani S, Kornder J, Lamy A, OMahony M, Pandey A, Sabe-Affaki G, St Maurice F, Adamkova V, Cermak O, Ceska R, Frana P, Hala T, Kellnerova I, Machkova M, Petrzelkova J, Pojsl S, Stankova V, Vaclavik J, Zemanek J, Krogsaa A, Nedergaard BS, Wermuth S, Clavel S, Cohen AA, Davy JM, Joubert M, Mansourati J, Probst V, Verges B, Degtyareva E, Förster A, Horacek T, Kasperk C, Kohler E, Laufs U, Meissner G, Schenkenberger I, Stoessel J, Trenk D, Winkler K, Lau EM, Yeung CY, Bajnok L, Bod E, Harcsa E, Lippai J, Mohacsi A, Palinkas A, Poor F, Szakal I, Sziegl Z, Borghi C, Bucci M, Cattin L, Iannuzzi A, Miccoli R, Passaro A, Pintus P, Pirro M, Sirtori C, Zambon S, De Graaf J, Donders S, Imholz B, Klessens-Godfroy F, Kooy A, Stroes E, Van Leendert R, Viergever P, Helder D, Vincent H, Barbarash O, Chumakova G, Demchenko E, Kotelnikov M, Litvin A, Lukyanov Y, Shvarts Y, Susekov A, Treshkur T, Yakhontova P, Gimilio JF, Gimeno EJ, Raya PM, Nuñez-Cortes JM, Prieto JM, Sala XP, Ros E, Borgencrantz B, Bosson P, Curiac D, Dahlén G, Delavaran C, Lindholm CJ, Burnier M, Eberli F, Gallino A, Mach F, Rickli H, Widmer F, Abdulhakim EE, Adler L, Blagden M, D'Costa R, Falk R, Fisher M, Hassanin H, Horvathova V, Kerrane J, Mackay J, McCormack T, McKinnon C, Oyesile B, Pavel-Knox I, Soran H, Thomas H, Abraham W, Aronoff S, Atassi K, Awasty V, Bailey K, Baron S, Bear R, Bertolet B, Bhagwat R, Coburn N, Connery L, Dauber I, Davis M, Diederich C, Eaton G, Fialkow J, Fishbein G, French W, Friedlander I, Fuchs-Ertman D, Ginsberg D, Hagan M, Hage-Korban E, Halpern S, Henderson D, Houser P, Ibrahim H, Jennings W, Kivitz A, Kozlowski L, Loh I, Malone M, McConnehey B, McCullum K, Miller M, Napoli M, Neutel J, Purdy D, Qureshi M, Ramstad D, Raoof T, Reichman A, Rich K, Robinson J, Rogers W, Salazar J, Shaoulian E, Stringer J, Tarleton G, Throne M, Webb C, Weiss R, Wiseman A.

Author information

Department of Epidemiology, College of Public Health, University of Iowa, Iowa City2Department of Medicine, College of Public Health, University of Iowa, Iowa City.
Center for Clinical and Basic Research, Aalborg, Denmark.
Division of Cardiovascular Disease, University of Alabama Medical Center, Birmingham.
Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami.
Orange County Research Center, Tustin, California.
Hampton Roads Center for Clinical Research, Suffolk, Virginia.
Amgen Inc, Thousand Oaks, California.
Maine Research Associates, Auburn.



In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.


To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin.


Phase 3, 12-week, randomized, double-blind, placebo- and ezetimibe-controlled study conducted between January and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries.


Patients (n = 2067) were randomized to 1 of 24 treatment groups in 2 steps. Patients were initially randomized to a daily, moderate-intensity (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastatin [5 mg]) or high-intensity (atorvastatin [80 mg], rosuvastatin [40 mg]) statin. After a 4-week lipid-stabilization period, patients (n = 1899) were randomized to compare evolocumab (140 mg every 2 weeks or 420 mg monthly) with placebo (every 2 weeks or monthly) or ezetimibe (10 mg or placebo daily; atorvastatin patients only) when added to statin therapies.


Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) level at the mean of weeks 10 and 12 and at week 12.


Evolocumab reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75% (95% CI, 65% to 84%) (every 2 weeks) and by 63% (95% CI, 54% to 71%) to 75% (95% CI, 67% to 83%) (monthly) vs placebo at the mean of weeks 10 and 12 in the moderate- and high-intensity statin-treated groups; the LDL-C reductions at week 12 were comparable. For moderate-intensity statin groups, evolocumab every 2 weeks reduced LDL-C from a baseline mean of 115 to 124 mg/dL to an on-treatment mean of 39 to 49 mg/dL; monthly evolocumab reduced LDL-C from a baseline mean of 123 to 126 mg/dL to an on-treatment mean of 43 to 48 mg/dL. For high-intensity statin groups, evolocumab every 2 weeks reduced LDL-C from a baseline mean of 89 to 94 mg/dL to an on-treatment mean of 35 to 38 mg/dL; monthly evolocumab reduced LDL-C from a baseline mean of 89 to 94 mg/dL to an on-treatment mean of 33 to 35 mg/dL. Adverse events were reported in 36%, 40%, and 39% of evolocumab-, ezetimibe-, and placebo-treated patients, respectively. The most common adverse events in evolocumab-treated patients were back pain, arthralgia, headache, muscle spasms, and pain in extremity (all <2%).


In this 12-week trial conducted among patients with primary hypercholesterolemia and mixed dyslipidemia, evolocumab added to moderate- or high-intensity statin therapy resulted in additional LDL-C lowering. Further studies are needed to evaluate the longer-term clinical outcomes and safety of this approach for LDL-C lowering.

TRIAL REGISTRATION: Identifier: NCT01763866.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center